February 28, 2020 / 12:19 PM / a month ago

BRIEF-Antibe Therapeutics Announces Enrollment Of Last Patient In Phase 2B Dose-Ranging, Efficacy Study Of Lead Drug, Atb-346

Feb 28 (Reuters) - Antibe Therapeutics Inc:

* ANTIBE THERAPEUTICS ANNOUNCES ENROLLMENT OF LAST PATIENT IN PHASE 2B DOSE-RANGING, EFFICACY STUDY OF LEAD DRUG, ATB-346

* ANTIBE THERAPEUTICS ANNOUNCES ENROLLMENT OF LAST PATIENT IN PHASE 2B DOSE-RANGING, EFFICACY STUDY OF LEAD DRUG, ATB-346

* ANTIBE THERAPEUTICS - CO ANTICIPATES RELEASE OF TOP-LINE RESULTS WITHIN SIX WEEKS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below